Exonic

Unsupervised Biological AI

Y CombinatorFall 2025ActiveHealthcareDrug Discovery and Delivery

What they do

Problem

Gene therapy development is constrained by limited ability to learn from heterogeneous, noisy biological data to predict and design safe, effective therapies.

Solution

Exonic builds unsupervised biological foundation models trained on large-scale unstructured data to enable zero-shot genomic regulation understanding and safer gene therapy design.

Who it's for

Biotech and pharmaceutical R&D teams developing gene therapies and genomic medicines.

Founders

Ben Brimacombe

Founder

Co-founded Free2Grow, one of the largest AI voice companies in the home services vertical today. Co-led Turnpoint contract ($1.4B revenue aggregator) at Free2Grow. Columbia Computer Science and Mathematics, 2020. Published AI researcher (EMNLP, 2023). Led machine learning at Long Run Partners, multi-hundred million dollar NYC mortgage bank (employee #9). Worked on ML team at Numerai, the crowdsourced hedge fund ($500m+ AUM).

LinkedIn · X